INO Quote, Financials, Valuation and Earnings

Lexicon Pharmaceuticals has a net margin of -30140.49% compared to Inovio Pharmaceuticals's net margin of -2004.36%. Inovio Pharmaceuticals's return on equity of -125.47% beat Lexicon Pharmaceuticals's return on equity of -90.8%.

Inovio Pharmaceuticals has a consensus price target of $7.50, signalling upside risk potential of 459.7%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $2.58 which suggests that it could grow by 100%. Given that Inovio Pharmaceuticals has higher upside potential than Lexicon Pharmaceuticals, analysts believe Inovio Pharmaceuticals is more attractive than Lexicon Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 1.307, which suggesting that the stock is 30.734% more volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.928%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $65.3K, which are smaller than Lexicon Pharmaceuticals quarterly revenues of $1.3M. Inovio Pharmaceuticals's net income of -$19.7M is higher than Lexicon Pharmaceuticals's net income of -$25.3M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 14.43x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics has a net margin of -30140.49% compared to Inovio Pharmaceuticals's net margin of -475.33%. Inovio Pharmaceuticals's return on equity of -125.47% beat Sangamo Therapeutics's return on equity of -269.87%.

Inovio Pharmaceuticals has a consensus price target of $7.50, signalling upside risk potential of 459.7%. On the other hand Sangamo Therapeutics has an analysts' consensus of $4.10 which suggests that it could grow by 751.86%. Given that Sangamo Therapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Sangamo Therapeutics is more attractive than Inovio Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 1.307, which suggesting that the stock is 30.734% more volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.402%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $65.3K, which are smaller than Sangamo Therapeutics quarterly revenues of $6.4M. Inovio Pharmaceuticals's net income of -$19.7M is higher than Sangamo Therapeutics's net income of -$30.6M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 1.60x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vaxart has a net margin of -30140.49% compared to Inovio Pharmaceuticals's net margin of -74.68%. Inovio Pharmaceuticals's return on equity of -125.47% beat Vaxart's return on equity of -94.14%.

Inovio Pharmaceuticals has a consensus price target of $7.50, signalling upside risk potential of 459.7%. On the other hand Vaxart has an analysts' consensus of $4.67 which suggests that it could grow by 1074.6%. Given that Vaxart has higher upside potential than Inovio Pharmaceuticals, analysts believe Vaxart is more attractive than Inovio Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 1.307, which suggesting that the stock is 30.734% more volatile than S&P 500. In comparison Vaxart has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.422%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vaxart offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Vaxart pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $65.3K, which are smaller than Vaxart quarterly revenues of $20.9M. Inovio Pharmaceuticals's net income of -$19.7M is lower than Vaxart's net income of -$15.6M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Vaxart's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 1.82x for Vaxart. Usually stocks with elevated PS ratios are considered overvalued.

Windtree Therapeutics has a net margin of -30140.49% compared to Inovio Pharmaceuticals's net margin of --. Inovio Pharmaceuticals's return on equity of -125.47% beat Windtree Therapeutics's return on equity of --.

Inovio Pharmaceuticals has a consensus price target of $7.50, signalling upside risk potential of 459.7%. On the other hand Windtree Therapeutics has an analysts' consensus of $4.00 which suggests that it could grow by 344.44%. Given that Inovio Pharmaceuticals has higher upside potential than Windtree Therapeutics, analysts believe Inovio Pharmaceuticals is more attractive than Windtree Therapeutics.

Inovio Pharmaceuticals has a beta of 1.307, which suggesting that the stock is 30.734% more volatile than S&P 500. In comparison Windtree Therapeutics has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.741%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Windtree Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Windtree Therapeutics pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $65.3K, which are larger than Windtree Therapeutics quarterly revenues of --. Inovio Pharmaceuticals's net income of -$19.7M is lower than Windtree Therapeutics's net income of -$4M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Windtree Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 0.42x for Windtree Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.